Therefore, it would be of interest to understand whether ETS2 acting as a transcription factor regulates a transcriptional programme in tumour-associated myeloid cells that is potentially associated with an immune reactive phenotype holding anti-tumoral properties, which would be repressed by the induction of ID2 expression in those cells. This evidence concerns the gene ID2 and neoplasm.